The effects of age and renal and hepatic impairment on the pharmacokinetics of sildenafil citrate

被引:90
作者
Muirhead, GJ
Wilner, K
Colburn, W
Haug-Pihale, G
Rouviex, B
机构
[1] Pfizer Ltd, Cent Res, Clin Sci, Sandwich CT13 9NJ, Kent, England
[2] Pfizer Inc, Global Res & Dev, San Diego, CA USA
[3] MDS Harris Labs Inc, Phoenix, AZ USA
[4] APEX Res, Munich, Germany
[5] Ctr European Pharmacol Clin, Strasbourg, France
关键词
sildenafil; UK-103,320; pharmacokinetics; elderly; renal impairment; hepatic impairment; safety;
D O I
10.1046/j.0306-5251.2001.00029.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Aims To investigate the effects of age and renal and hepatic impairment on the pharmacokinetics, tolerability and safety of sildenafil (single 50-mg oral dose) and its major circulating N-desmethyl metabolite, UK-103,320. Methods Three open-label, parallel-group studies were conducted. The first study compared sildenafil pharmacokinetics, safety and toleration in 15 healthy young male subjects (mean age 30 years; range 19-45 years) to 15 health,,, elderly male subjects (mean age 70 years; range 65-81 years). The second study included eight male volunteers with normal renal function and 16 male volunteers with varying degrees of renal impairment as assessed by measurement of creatinine clearance (CLcr). The third study included 12 male volunteers with normal hepatic function and 12 male volunteers with chronic stable hepatic cirrhosis (Child-Pugh A and 13). For all three studies, blood and urine samples were collected predose and at specified intervals up to 48 h postdose for assays of sildenafil and UK-103,320, and measurements of protein binding. Results Significant differences in C-max and AUC were observed between the young and the elderly subjects for both the parent drug and the metabolite. In the elderly, AUC values were approximately twice as high and C-max values 60-70% higher than those for young men, while t(1/2) values were approximately 1 h longer for sildenafil and 2 h longer for UK-103,320. Due to a significantly smaller unbound fraction of drug in the elderly, free drug concentrations were only approximately 40% higher in the elderly group compared to the young group. In the renal impairment study, significant correlations with CLcr were demonstrated for sildenafil oral clearance (CL/F) and C-max and UK-103,320 C-max and AUC. Pairwise comparisons between Subjects with normal renal function and those with severe renal impairment (CLcr < 30 ml min(-1)) supported these findings, showing significant increases in C-max. and AUC for both the parent drug and the metabolite in the severely impaired subjects. The hepatic impairment study demonstrated that the pharmacokinetics of sildenafil were altered in subjects with chronic stable cirrhosis, as shown by a 46% reduction in CL/F and a 47% increase in C-max. compared with subjects with normal hepatic function, suggesting a reduction in first-pass metabolism as well as systemic clearance. The increase in systemic exposure for UK-103,320 was approximately twice that seen for the parent drug. In all three studies, sildenafil was well tolerated. most adverse events were mild and no subjects discontinued treatment. Conclusions Sildenafil pharmacokinetics were affected by age and by renal and hepatic impairment, suggesting that a lower starting dose of 25 mg should be considered for patients with severely compromised renal or hepatic function.
引用
收藏
页码:21S / 30S
页数:10
相关论文
共 16 条
  • [1] Boolell M, 1996, Int J Impot Res, V8, P47
  • [2] Development of an assay for the simultaneous determination of sildenafil (Viagra) and its metabolite (UK-103,320) using automated sequential trace enrichment of dialysates and high-performance liquid chromatography
    Cooper, JDH
    Muirhead, DC
    Taylor, JE
    Baker, PR
    [J]. JOURNAL OF CHROMATOGRAPHY B, 1997, 701 (01): : 87 - 95
  • [3] DROLLER MJ, 1993, JAMA-J AM MED ASSOC, V270, P83
  • [4] Feldmann J., 1954, TRAV STAT BIOL ROS S, V6, P1
  • [5] Oral sildenafil in the treatment of erectile dysfunction
    Goldstein, I
    Lue, TF
    Padma-Nathan, H
    Rosen, RC
    Steers, WD
    Wicker, PA
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1998, 338 (20) : 1397 - 1404
  • [6] Effects of sildenafil, a type-5 cGMP phosphodiesterase inhibitor, and papaverine on cyclic GMP and cyclic AMP levels in the rabbit corpus cavernosum in vitro
    Jeremy, JY
    Ballard, SA
    Naylor, AM
    Miller, MAW
    Angelini, GD
    [J]. BRITISH JOURNAL OF UROLOGY, 1997, 79 (06): : 958 - 963
  • [7] The aging liver - Drug clearance and an oxygen diffusion barrier hypothesis
    Le Couteur, DG
    McLean, AJ
    [J]. CLINICAL PHARMACOKINETICS, 1998, 34 (05) : 359 - 373
  • [8] THE EFFECT OF RENAL IMPAIRMENT ON THE PHARMACOKINETICS AND METABOLISM OF BOPINDOLOL
    MACDONALD, NJ
    GRANT, AC
    RODGER, RSC
    MEREDITH, PA
    ELLIOTT, HL
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1991, 31 (06) : 697 - 700
  • [9] Sildenafil, a novel inhibitor of phosphodiesterase type 5 in human corpus cavernosum smooth muscle cells
    Moreland, RB
    Goldstein, I
    Traish, A
    [J]. LIFE SCIENCES, 1998, 62 (20) : PL309 - PL318
  • [10] CLINICAL PHARMACOKINETIC AND PHARMACODYNAMIC CONSIDERATIONS IN PATIENTS WITH LIVER-DISEASE - AN UPDATE
    MORGAN, DJ
    MCLEAN, AJ
    [J]. CLINICAL PHARMACOKINETICS, 1995, 29 (05) : 370 - 391